Tolerability and safety of galcanezumab in patients with chronic cluster headache with up to 15  months of galcanezumab treatment

CONCLUSIONS: Galcanezumab 300 mg monthly had a favorable tolerability and safety profile in patients with chronic CH with up to 15 months of treatment.PMID:34806783 | DOI:10.1111/head.14234
Source: Headache - Category: Neurology Authors: Source Type: research